TrinityPoint Wealth LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

TrinityPoint Wealth LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 85.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 191,544 shares of the biopharmaceutical company’s stock after buying an additional 88,258 shares during the quarter. Pfizer accounts for approximately 0.8% of TrinityPoint Wealth LLC’s portfolio, making the stock its 27th biggest position. TrinityPoint Wealth LLC’s holdings in Pfizer were worth $5,543,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $315,000. Edgestream Partners L.P. acquired a new position in shares of Pfizer during the first quarter worth $243,000. Hillsdale Investment Management Inc. increased its holdings in Pfizer by 111.3% in the first quarter. Hillsdale Investment Management Inc. now owns 3,132 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 1,650 shares during the last quarter. Rockport Wealth LLC acquired a new stake in Pfizer in the first quarter valued at $294,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in Pfizer by 7.1% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 317,495 shares of the biopharmaceutical company’s stock worth $8,810,000 after buying an additional 20,950 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.80 on Monday. The stock has a fifty day moving average price of $28.64 and a 200 day moving average price of $28.67. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $140.54 billion, a PE ratio of 33.51, a P/E/G ratio of 0.79 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.77%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.